---
title: Prognosis of myelodysplastic syndromes
date: "2023-01-22"
enableToc: false
---

> [!info]
>
> ğŸŒ± ä¾†è‡ª: [[myelodysplastic syndromes]]

# Prognosis of myelodysplastic syndromes

- mutations inTP53, ASXL1, cZH2, RUNX1, ETV6 (NEJM 2011; 364:2496) â†“ survival

  - åœ¨ TP53ã€ASXL1ã€cZH2ã€RUNX1ã€ETV6 åŸºå› ä¸­çš„çªè®Šæœƒå°è‡´æ‚£è€…çš„ç”Ÿå­˜ç‡ä¸‹é™ã€‚

- IPSS scoreâ€”commonly used & best validated prognostic scoring system
- Correlates w/ OS & evolution to AML (Blood 1997;89:2079)

---

![ğŸ–¼ï¸ Figure: _](https://i.imgur.com/KyAgcG5.png)

---

- Revised IPSS (IPSS-R) score:
  - Assigns greater prognostic significance to cytogenetics & utilizes 5 rather than 3 prognostic subgroups; uses modified cytopenia thresholdsâ€”neutropenia as <800/uL vs. <1,800/uL (Blood 2012;120:2454)
- Complex karyotype & t-MDS have poor prog, as do Mts in TP53, EZH2, ETV6, RUNX1 & ASXL1 (NEJM 2011:364:2496); poor outcomes observed w/ TP53 Mts are specific to biallelic TP53 loss but not monoallelic TP53 Mts (Nature Med 2020;26:1549)
